Navigation Links
Essential Pharmaceuticals Acquires Exclusive Worldwide Rights to Family of Cell Media Products from Lifeblood Medical
Date:10/27/2010

NEWTOWN, Pa., Oct. 27 /PRNewswire/ -- Essential Pharmaceuticals, LLC, a private company dedicated to providing specialty reagents and solutions to the life sciences market, announced today that the Company will commence sales and distribution of three distinct animal-component-free products: serum replacement, cryopreservation and clinical pathology media, formerly sold under the LiforCell® name:

  • Cell-Ess™ Serum Replacement cell culture medium,
  • Cryo-Ess™ cryopreservation medium, and
  • Clin-Ess™ transportation medium.

"The quality and consistency of Cell-Ess, Cryo-Ess and Clin-Ess gives scientists the confidence to conduct their research without testing each new serum lot purchased, resulting in improved laboratory efficiency and valuable cost savings," said Allan Weber, chief executive officer of Essential Pharmaceuticals.  "Moreover, we believe that the characteristics of these media products offer important clinical benefits, making Cell-Ess the ideal choice for use in the cutting edge areas of stem cell, cancer and vaccine research, and Clin-Ess in the preservation of limbs and organs for surgical applications."  

The Cell-Ess, Cryo-Ess and Clin-Ess family offers researchers the advantage of superior performance compared to fetal bovine serum. They are free of all animal components and dimethyl sulfoxide (DSMO), do not crystallize or form ice during the thawing process, resulting in less DNA and RNA degradation and fewer artifacts than those preserved using conventional methods. Further, they have demonstrated synthetic reproducibility with no lot-to-lot variability.  

Essential Pharmaceuticals acquired exclusive worldwide rights to these media products, originally the LiforCell® family of products, from Lifeblood Medical, Inc. These cell culture and cryopreservation products have been re-branded to correlate to their specific research and clinical applications.  

"Essential Pharmaceuticals is known for its outstanding customer support in highly specialized fields," stated Joseph Fischer, President and Chief Executive Officer of Lifeblood Medical. "That, along with the superior advantages of these cell culture and cryopreservation media, will generate increased growth and market penetration of the Lifeblood technology."

About Essential Pharmaceuticals

Essential Pharmaceuticals LLC, a key company in the organ transplant arena, provides Custodiol® HTK organ preservation solution to the transplant medical community.  Essential is well-known for excelling in highly specialized medical areas through a combination of outstanding customer support coupled with customized distribution systems and ongoing research projects to further knowledge in the field of organ preservation.  Essential plans on bringing this proven model to support medical researchers and further their projects, improving future medical discoveries globally.

For additional information about Essential Pharmaceuticals new family of cell media products, or any other Essential product, please visit our website at www.essentialpharma.com, e-mail to info@essentialpharma.com or call 1-267-757-0112.

*CUSTODIOL® HTK is a registered trademark of Dr. Franz Kohler Chemie GmbH, Alsbach-Hahnlein, Germany.

*LiforCell® is a registered trademark of Lifeblood Medical, Inc.


'/>"/>
SOURCE Essential Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
2. Laerdal Introduces SimMan Essential
3. Health Outcomes Data Essential to Biopharmaceutical Sales Process
4. Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds
5. Weekly Digests Investor Essentials Special Report Identifies Unique Investing Opportunities in the H1N1 Swine Flu Outbreak
6. Essentialis to Submit SPA for Hypertriglyceridemia
7. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
8. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
9. Precise Low-Dose Drug Monitoring Essential for Long-Term Kidney Transplant Success
10. Nationwide Survey Reports that Mothers View Cleaning Homes and Toys as Essential to Preventing Colds & Flu
11. Teva Pharmaceuticals and the Philadelphia Eagles Award Four Grants to Greater Philadelphia Area Service Organizations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Cardiovascular Surgery Devices - Medical ... Medical Devices sector report, "Cardiovascular Surgery Devices - ... of Cardiovascular Surgery Devices currently in pipeline stage. ... The report provides comprehensive information on the pipeline ... various stages of development. The report reviews major ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
(Date:2/8/2016)... February 8, 2016 --> ... research report "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, ... Management, Cosmetic Surgery, Ophthalmology, Gynecology) - Global Forecasts to ... market over the forecast period of 2015 to 2020. ... 2020, at CAGR of 10.5% from 2015 to 2020. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... BASF Human Nutrition into the Food & Beverage and Dietary ... BASF’s channel partner throughout Canada and USA geographies east of the Rocky Mountains ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Valentine’s Season is famous for gift giving with flowers, ... that they are loved. This year, for more than 5.6 million Americans suffering with ... won't be enough to remind them of the lives they’ve led and the people they’ve ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your ... are not alone. According to the Center for Disease Control and Prevention (CDC), 34.9% ... diabetes and certain types of cancer, some of the leading causes of preventable death. ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... IN metro area, has selected the latest beneficiary of their ongoing community enrichment ... to preventing bullying in area schools. Donations are now being accepted at: ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted February 8, ... West Awards. , Awards include the Information Security Executive® of the ...
Breaking Medicine News(10 mins):